Bring immune system on step Ahead cancer
An allogeneic platform to generate first in class Immune Therapy ambitionning to harness patient immune system and prevent cancer resistance over treatment.
0%
of currently treated
patients for solid tumors will experience a treatment failure.
Our mission at Brenus is to provide a solution in cold solid tumors, today’s most important unmet need in oncology.
Cancer = A moving target
Efficacy of current approaches is compromised by drug resistances within the tumor, which is a scalable process. The population of cells constantly shifts during therapy defining cancer as a ‘moving target’.
Our technology leverages three major pillars, in a single solution. To harness a specific, highly potent And durable immune response
STC platform
Representativity
Strict and AI assisted selection of Specific allogeneic Tumor cell lines to be the most representative of the targeted indication.
Representativity
Back to science
The scalable and unique STC Platform is an allogenic technology wich mimics and represents the cellular heterogeneity of the patient’s tumor. The REPRESENTATIVITY (diversity) is ensured by cell lines selected in data base and with in vitro test. (cold tumor, hot tumor, oncogenic drivers : TP53, BRAF, KRAS,….).
Antigenicity
STC technology allows to educate the immune system with the widest panel of neoantigens of interest.
Antigenicity
Back to science
Our technology prepares and trains the representative cells of interest: 1st physical exposition (low radiation – heatchock) and a second chemical one (clinical cytotoxic molecules). The ANTIGENICITY (plasticity) of our solution is ensured by more than 200 neo antigens expressed on the cell surface. The neo antigens are TAA (tumor Asossiated Antigens) – TSA (Tumor Specific Antigens) which constitute the largest panel of resistance factors.
Immunogenicity
An haptenization proccess educates a patient’s immune system to recognized and turn target protein as visible, enhancing a more potent immune response.
Immunogenicity
Back to science
In a very innovative way, and to ensure the IMMUNOGENICITY of our solution, a recognition tag associated with surface neoAntigens is added by Haptenization. This step makes the solution, already representative and antigenic, visible by the patient’s immune system, therefore very Immunogenic.
Our lead candidate, STC-1010 will target metastatic colorectal cancer
Facts about colorectal cancer
-
2 millions patients diagnosed every year
-
2nd cause of cancer mortality worldwide
-
12% survival rate at 5 years
Our response
-
To meet the need to target treatement resistance
STC-1010 is targeting MSS and MSI-H population
-
To meet the need to breaking immune tolerance
STC-1010 has a robust and validated preclinical data pack showing
- an increase in overall survival in colorectal cold and hot mice model,
- an increase in CD8+ Tumor Infiltration in several model,
- an efficacy in AntiPD1 resistant mice model.
-
To meet the need for an acceccible approche
An OFF-THE-SHELF technology allowing control on time and cost of the manufacturing process
Our product
J. GardetteFounder & President
Back to experts
Successful IPO
Successful exits to top Healthcare companies
B. PinteurFounder & Chief Scientific officer
Back to experts
GMP manufacturing of cell therapies and vaccines
Previous roles at Roche, Merck
Pharm D
E. DessertenneChief Executive Officer
Back to experts
IPO & Licencing deals (< 100 M e) / Life science & Private Equity
Previous roles at LEK Consulting, Biocorp
Pharm D ; ESSEC
P. BravettiChief Operating officer
Back to experts
Specialized in medical oncology & immunooncology
Previous roles at Roche, Takeda Oncology
Pharm D ; HEC Paris
S. PetitetHEad of External affairs
Back to experts
Specialized in innovative therapies : Gene, Stem cell, RNA, …
Previous roles at Merck, Biogen, Chieisi
MSc
Dr F. GhiringhelliHead of Scientific Board
CGFL, Dijon (FR)
Dr F. GhiringhelliHead of Scientific Board CGFL, Dijon (FR)
MD, PhD, Director of early clinical unit,
head of “Cancer and adaptative immune response” team,
INSERM/CLIPP2
CGFL, Dijon (FR).
Dr C. GongoraIRCM, Montpellier (FR)
Dr C. GongoraIRCM, Montpellier (FR)
PhD. Head of Preclinical study department
“drug resistance and new cancer therapies”,
IRCM, Montpellier (FR)
Pr A. ItalianoInstitut Bergonié, Bordeaux
Intsitut Gustave Roussy,
Paris (FR)
Pr A. ItalianoInstitut Bergonié, BordeauxIntsitut Gustave Roussy,
Paris (FR)
Head of Early Phase Trials and Sarcoma units; Institut Bergonié, Bordeaux (FR)
Head of Precision medicine new program; Intsitut Gustave Roussy, Paris(FR)
Pr B. YouHCL, Lyon (FR)
Pr B. YouHCL, Lyon (FR)
MD, PhD. Coordinator of early phase oncology trial CITOHL
HCL, Lyon (FR)
Pr M. YarchoanJohns Hopkins, Baltimore (US)
Pr M. YarchoanJohns Hopkins, Baltimore (US)
MD, PhD. Dept Discovery of novel cancer I/O & vaccins,
Johns Hopkins, Baltimore (US)
Pr A. AwadaJules Bordet Cancer Institute, Brussels (BE)
Pr A. AwadaJules Bordet Cancer Institute, Brussels (BE)
MD, PhD., Head of European network of academic lead investigators for innovative clinical research ONCODISTINCT.
Head of The Oncology Medicine Dept at Jules Bordet Cancer Institute, Brussels (BE)